European Society of Toxicology In Vitro > Newsletters

Newsletter No. 46 – 2020 Spring

Dear ESTIV members,

First and foremost, I hope all of you as well as your family, beloved ones, friends and colleagues are safe and sound. We are facing challenging times to say the least. The COVID-19 crisis is impacting all of us directly or indirectly. My thoughts go to the many patients and victims, and I want to express my sincere appreciation to the frontline caregivers as well as to all other people worldwide who in one or the other way help to defeat the Coronavirus. This is a time where we have to deal with grief and sorrow, but we also see a lot of empathy, solidarity and unity. In this respect, I want to greatly thank our members, speakers, sponsors and exhibitors for the understanding and flexibility regarding the decision of the ESTIV Board to postpone both the “Applied In Vitro Toxicology Course” (new dates: 25-30 October 2020) and the “21st ESTIV Congress” (new dates: 22-26 November 2022), taking place in Brussels-Belgium and Sitges-Spain, respectively.


This first newsletter of 2020 will be my last one as ESTIV President. I had the great honor to serve the ESTIV Board for a full decade, first as responsible for student affairs (2010-2012), subsequently as Vice-President (2012-2016) and finally as President (2016-2020). This has been an intensive yet pleasant experience for me with a lot of new collaborations and great friendships. I am very proud of what the current and former ESTIV Boards have accomplished in those 10 years, including the organization of a plethora of workshops, courses, webinars and conferences as well as a considerable extension of our network by teaming up with various societies around the globe. I would like to thank all ESTIV Board members, but in particular all the regular members, corporate members, sponsors, affiliated and memorandum of understanding societies for the confidence, support, interest and active participation in the ESTIV events. The ESTIV Presidency will now be taken over by Dr. Helena Kandárová, who joined the ESTIV Board in 2014. I am fully confident in Helena and the entire renewed ESTIV Board, all who are very committed to pursue the ESTIV activities in the upcoming years.

Prof. Mathieu Vinken, PhD, PharmD, ERT
ESTIV President

Link to the newsletter No. 45:

Newsletter No. 45 – 2019 Autumn

Dear ESTIV members,

At the start of this second newsletter of the year, I am happy to announce that ESTIV now has a brand new website, which, along with our presence on social media, will be the main tool to communicate with our members to advertise our events. In this respect, 2019 has been very productive and successful for ESTIV thus far. Indeed, together with the American Society for Cellular and Computational Toxicology (ASCCT), ESTIV has organized 9 free webinars presented by researchers from Europe and the US on topics related to in vitro and/or in silico toxicology since January. Another ESTIV-ASCCT joint activity included the fifth edition of the Applied In Vitro Toxicology Course that was organized in Bucharest-Romania from 14 to 19 April and that was attended by 31 participants coming from 13 different countries. Of note, this course is now recognized by EUROTOX as part of the European Registered Toxicologist (ERT) accreditation program. In May this year, a Memorandum of Understanding was signed between ESTIV and the European Society Animal Cell Technology (ESACT). The goal of this Memorandum of Understanding is to provide members of the societies involved a greater platform in which to develop and share their expertise on 3Rs approaches, in particular with respect to in vitro toxicology. Furthermore, ESTIV has granted and number of travel bursaries and awards to early-stage researchers, and was represented during several congresses and workshops, some for which a report is provided in the present newsletter. ESTIV is now getting ready for 2 new major events taking place in 2020. The first event is the sixth edition of the “Applied In Vitro Toxicology Course” that will be organized from 5 to 10 April 2020 in Brussels-Belgium in collaboration with the Belgian Society of Toxicology and Ecotoxicology (BelTox), the Université Catholique de Louvain (UCLouvain) and MatTek In Vitro Life Science Laboratories s.r.o. The second event includes the 21st international congress of ESTIV taking place from 8 to 11 June 2020 in Sitges near the city of Barcelona-Spain. ESTIV will grant for the very first time an early-career award during its congress in Spain and intends to do so every 2 years as of now. The Award will be given to an early-career scientist in recognition of an outstanding and significant contribution to the field of in vitro and/or in silico toxicology.

I hope to welcome you during these events in Brussels and Barcelona!
In the meanwhile, I hope you will enjoy this newsletter and I wish you a warm and productive autumn and winter.

Prof. Mathieu Vinken, PhD, PharmD, ERT
ESTIV President


Link to the newsletter No. 45

Newsletter No. 44 – 2019 Spring

Dear ESTIV Members,
In this first newsletter of 2019, I am proud to announce that the ESTIV2018 conference (15-18 October 2018, Berlin-Germany) has been the most successful ESTIV meeting in its history. Indeed, this 20th ESTIV conference has hosted 447 participants from 45 countries worldwide and received a total of 285 abstracts. You will read several contributions related to ESTIV2018 in this newsletter. Besides the scientific program, several other important events took place during ESTIV2018, including signing a new Memorandum of Understanding with the Japanese Society for Alternatives to Animal Experiments (JSAAE) and granting ESTIV honorary membership to Chantra Eskes. Along with Laura Suter-Dick, Eleonora Buzanska and Philippe Bourrinet, Chantra Eskes left the ESTIV Board during the ESTIV General Assembly (17 October 2018, Berlin-Germany) because of end of term. The ESTIV Board is grateful to all 4 of them for their years of commitment and contribution to ESTIV. A number of new ESTIV Board members have been welcomed during the ESTIV General Assembly, including Erin Hill and Hajime Kojima, American Society for Cellular and Computational Toxicology (ASCCT) liaison and JSAAE liaison, respectively. Many activities are upcoming. ESTIV will also continue to organize free webinars together with ASCCT and invites its members to propose relevant topics to be covered during these webinars. Furthermore, ESTIV will be represented during annual international toxicology conferences, including the EUROTOX meeting. You will read more about this in the current newsletter. I hope you find the information provided in this newsletter useful.

Prof. Mathieu Vinken, PhD, PharmD, ERT
ESTIV President


Link to the newsletter No. 44

Corporate Members

mattek in Vitro Life Science Laboratories

Affiliated Societies

Invitrom Celltox IVTS

Memorandum of Understanding